Besides the now approved remdesivir: Emerging options to treat Covid-19

Last Updated on

May 03, 2020 –  The world is desperate in the search for a treatment or better yet a vaccine in the Covid-19 pandemic. Slowly, there are some options emerging at least for the treatment of seriously ill Covid-19 patients. First of all,  the American Food and Drug Administration just issued an emergency use authorization (EUA) for the investigational antiviral drug remdesivir for the treatment of suspected or laboratory-confirmed COVID-19 in adults and children hospitalized with severe disease. While there is limited information known about the safety and effectiveness of using remdesivir to treat people in the hospital with COVID-19, the investigational drug was shown in a clinical trial to shorten the time to recovery in some patients.

SARS-Cov-2 Interactome

Remdesivir is the first example of a candidate drug being repurposed towards treatment of Covid-19 disease from its original use in the treatment of the Ebola disease in the West African Ebola virus epidemic of 2013–2016 and also during the 2018  Kivu Ebola epidemic in the Democratic Republic of Congo.

Along these lines of repurposing drugs, early data on such efforts show that almost a dozen approved drugs could be effective against Covid-19 disease. Thus, according to a multidisciplinary study conducted by a large team of scientists in the United States and France that has just appeared in the Journal Nature, at least 10 different drug compounds ranging from cancer therapies to antipsychotics and antihistamines may be effective at preventing the SARS-CoV-2 from multiplying in the body.

The researchers mapped the human proteins SARS-CoV-2 interacts with inside the body when it infects cells and makes copies of itself, then looked for compounds that could block the virus from using those proteins, giving rise to a SARS-CoV-2 interactome. The result showed that 47 compounds in cell cultures had the desired effect, at least 10 of which are already in approved drugs or being studied for diverse conditions, but could be repurposed against COVID-19, the illness caused by SARS-CoV-2. In the study, candidates for repurposing included allergy medicine ingredients including clemastine, the antipsychotic haloperidol, and malaria drug hydroxychloroquine

Particularly the latter has stirred some controversy in the media and even among the clinical research community when it comes to a possible role of hydroxychloroquine as a treatment of Covid-19. Hydroxychloquine, sold, among others, under the brand name Plaquenil, is a medication used to prevent and treat malaria in areas where malaria remains sensitive to chloroquineOther indications include rheumatoid arthritis, lupus, and porphyria cutanea tarda. In all these indications, side effects include vomiting, headache, changes in vision, and muscle weakness as well as more serious effects such as   allergic reactions, vision problems, and heart problems. Nevertheless, and despite some controversial study results about effectiveness and safety, hydroxychchloroquine remains one of the options of a repurposed drug for Covid-19 treatment.

By means of the SARS-CoV-2 interactome approach in the present study, a number of additional compounds have been identified with the potential of effectivity in the treatment of Covid-19. These include the experimental chemical, PB28, was 20-times more potent than hydroxychloroquine in targeting the cellular receptor for SARS-CoV-2, the hormone progesterone, and the antiviral plitidepsin, the pharmacologically active ingredient in Madrid-based PharmaMar’s experimental cancer therapy Aplidin. There are some interesting notions to these compounds. First, Plitidepsin is currently already being tested in Covid-19 trials in Spain. Secondly, Progesterone may help to explain some aspects of the fact that men seem more often affected than women and often show more serious disease progressions. And last but not least, the experimental chemical PB28 exhibited significantly less affinity than hydroxychloroquine for a heart protein which may be at the root for the known heart toxicity of hydroxychloroquine in some patients.

Some of the drugs and compounds tested in the researchers SARS-CoV-2 interactome approach have turned out, at least in the  laboratory setting, many times more potent than remdesivir. All these compound may be candidates for repurposing after thorough further in vitro and in vivo (i.e., clinical) development.

See here a sequence on how current drugs are being repurposed to possibly fight coronavirus (Covid-19):

Print Friendly, PDF & Email

Tags: , , , , , , , , , , , , , , , , ,
About the Author
Joseph Gut - thasso Ph.D.; Professor in Pharmacology and Toxicology. Senior expert in theragenomic and personalized medicine and individualized drug safety. Senior expert in pharmaco- and toxicogenetics. Senior expert in human safety of drugs, chemicals, environmental pollutants, and dietary ingredients.

Your opinion


No comments yet

thasso: conditions

thasso: newest tweets

thasso: recent comments

View my Flipboard Magazine.

thasso: categories

thasso: archives

thasso: simple chat

You must be a registered user to participate in this chat.

  • Newly discovered mutation could point to heart disease therapeutic target August 7, 2020
    New work led by Carnegie's Meredith Wilson and Steve Farber identifies a potential therapeutic target for clogged arteries and other health risks that stem from an excess of harmful fats in the bloodstream. Their findings are published by PLOS Genetics.
  • Genetic cause of congenital malformation discovered August 7, 2020
    Spontaneous mutations of a single gene are likely to cause serious developmental disorders of the excretory organs and genitalia. This is shown in an international study led by the University of Bonn and published in the journal Frontiers in Cell and Developmental Biology. The researchers also owe their findings to an unusual model organism: the […]
  • Novel approach reduces SCA1 symptoms in animal model August 7, 2020
    Research has shown that a mutation in the ATAXIN-1 gene leads to accumulation of Ataxin-1 (ATXN1) protein in brain cells and is the root cause of a rare genetic neurodegenerative disease known as spinocerebellar ataxia type 1 (SCA1). How healthy cells maintain a precise level of ATXN1 has remained a mystery, but now a study […]
  • Alport Syndrome: Research highlights link between genotype and treatment effectiveness August 7, 2020
    A large-scale analysis of the clinical characteristics of Alport syndrome in Japanese patients has revealed that the effectiveness of existing treatment with ACE inhibitors and/or angiotensin receptor blockers (RAS inhibitors) varies depending on the type of mutation in the syndrome's causal gene (COL4A5). RAS inhibitors are widely administered to patients with chronic kidney diseases as […]
  • Tasmanian devil research offers new insights for tackling cancer in humans August 6, 2020
    A rare, transmissible tumor has brought the iconic Tasmanian devil to the brink of extinction, but new research by scientists at Washington State University and the Fred Hutchinson Cancer Research Center in Seattle indicates hope for the animals' survival and possibly new treatment for human cancers.
  • checkmate 743 shows that dual immunotherapy, nivolumab + ipilimumab August 8, 2020
    The combination of first-line nivolumab and ipilimumab demonstrated an improvement of overall survival for patients with unresectable malignant pleural mesothelioma compared to platinum-based chemotherapy, according to research presented today at the International Association for the Study of Lung Cancer Virtual Presidential Symposium.
  • Phase 3 eXalt3 study shows significantly longer progression-free survival August 8, 2020
    Patients with non-small cell lung cancer (NSCLC) carrying anaplastic lymphoma kinase (ALK) gene alterations who received ensartinib experienced substantially longer progression-free survival than a matched group of patients who received crizotinib.
  • Addition of sintilimab to pemetrexed and platinum improved progression-free survival August 8, 2020
    The interim analysis of ORIENT-11, a phase III double-blind randomized trial has shown a nearly two-fold increase in progression-free survival with addition of sintilimab to chemotherapy in patients with advanced or metastatic non-squamous non-small cell lung cancer without EGFR or ALK genomic aberrations, according to research data presented today at the International Association for the […]
  • Heart attack case rates, treatment approaches, outcomes during COVID-19 pandemic August 7, 2020
    The increases and decreases in patient volume and associated changes in treatment experienced by individuals presenting with acute heart attack (myocardial infarction) before and immediately after the onset of the COVID-19 pandemic are examined in this observational study.
  • COVID recovery choices shape future climate August 7, 2020
    A new international study, led by the University of Leeds, warns that even with some lockdown measures staying in place to the end of 2021, without more structural interventions global temperatures will only be roughly 0.01°C lower than expected by 2030. However, the study estimates that including climate policy measures as part of an economic […]